Results 231 to 240 of about 1,875,854 (282)

Extracellular Vesicle‐Transferred ATP‐Citrate Lyase Induces Monocyte Differentiation Toward Tumor‐Associated Macrophages and Fuels Hepatocellular Carcinoma Progression

Advanced Science, EarlyView.
Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu, Haihong Lai, Qing Yang, Chaoyue Zhang, Bin Jia, Qiyi Chen, Yuling Deng, Fen Cao, Yuyu You, Zhe Li, Dongming Kuang, Bo Li   +11 more
wiley   +1 more source

Comparative safety of PD-1 and PD-L1 inhibitors in advanced solid tumors: a real-world cohort study with competing risk analysis. [PDF]

Cancer Immunol Immunother
Shih YH, Wang SJ, Fan CT, Lu TF, Chen YF, Sun L, Hsu ST, Tseng JJ, Lu CH.   +8 more
europepmc   +1 more source

Chemically Engineered L. reuteri Delivering αPD‐L1 and Gallium Ions via Metal‐Phenolic Networks Potentiate Anti‐Tumor Immunity and Ferroptosis

Advanced Science, EarlyView.
A multifaceted chemical strategy, integrating bacterial tropism, metal‐ion interference therapy, and immunotherapy, resulted in significant tumor regression in murine models. A pioneering paradigm for the design of biohybrid materials was established, highlighting how sophisticated chemical engineering of living systems can unlock new avenues for ...
Tingting Zhang, Mengyi Xu, Yan Zhang, Zhiwen Li, Danqing Song, Jing Pang, Ke Li, Yanxiang Wang   +7 more
wiley   +1 more source

Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer. [PDF]

Hum Vaccin Immunother
Mao Y, Xing N, Sun W, Bao X, Liu X, Wu R, Peng J.   +6 more
europepmc   +1 more source

Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects

Advanced Science, EarlyView.
Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang, Tianyu Shao, Fengjiang Qu, Caiyun Bai, Sijie Li, Pin Gao, Wenna Li, Keman Cheng, Xiao Zhao, Zhimin Fan   +9 more
wiley   +1 more source

PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer. [PDF]

J Immunother Cancer
Chen Y, Liu X, Hu Y, Li A, Zeng B, Wang P, Tang G, Jiang B, Yuan H, Jiang L.   +9 more
europepmc   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin, Dingqin Cai, Chunli Jian, Yaxian Qi, Linpeng Zheng, Qiao Yang, Longyao Zhang, Diangang Chen, Lingchen Li, Ping Cai, Lingyou Sun, Luping Zhang, Jianguo Sun   +12 more
wiley   +1 more source

Tailoring exciplex formation in metal-induced supramolecular organization.

Dalton Trans
Le-Hoang G, Guénée L, Piguet C.
europepmc   +1 more source

Photodynamic therapy with zinc phthalocyanine suppresses immune checkpoints in human melanoma cells. [PDF]

Lasers Med Sci
Doustvandi MA, Hajizadeh M, Mohammadnejad F, Karamali N, Yari AH, Nobari SA, Baradaran B.   +6 more
europepmc   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source